Date and time
Start: Thursday 30 January 2020, 12:30 PM
End: Thursday 30 January 2020, 01:30 PM
Thursday 30 January
Start: Thursday 30 January 2020, 12:30 PM
End: Thursday 30 January 2020, 01:30 PM
The ability to overcome obviousness rejections under 35 U.S.C. 103 before the USPTO is a key skill for patent practitioners. Recent USPTO statistics show that obviousness rejections are issued in 79% of office actions with at least one rejection. How can you win key patent rights for your clients as anticipation rejections wane in popularity and frequency, and obviousness rejections rage? We will discuss obviousness at a foundational level and progress to drafting strategies and practice tips to help you overcome obviousness at the USPTO.
Fellows, Students
As a practitioner, Loren has developed, managed, and protected both large and small domestic and foreign patent and trademark portfolios. His wide-ranging biotech and pharmaceutical experience includes advising clients how to protect small molecule and peptide drugs, methods of treatment, genetic constructs and therapies, nucleotide analogs, and RNA related drug technologies. He has also counseled clients developing medical devices such as optically-guided feeding tubes, injectors, diagnostic kits, catheters, and cardiac assist devices. In the chemical arena, Loren’s experience includes assisting clients to protect solid oxide fuel cell technologies, ionically-conductive membrane applications, and syngas production techniques.
The event has been added to your basket:
Sign in to your account to register for the event
If you are not yet registered or a member of CIPA, please register here